Aspirin desensitization is a medical procedure where a person who reacts badly to aspirin is given gradually increasing doses under close supervision until their body stops reacting. Once desensitized, the person can tolerate aspirin and often benefits from taking it daily as a treatment. The procedure is most commonly used for a condition called aspirin-exacerbated respiratory disease (AERD), though it also has applications for certain heart patients who need aspirin but can’t tolerate it.
Why Some People Need It: AERD
The primary reason for aspirin desensitization is AERD, sometimes called Samter’s triad. AERD is an acquired inflammatory condition defined by three overlapping problems: asthma, chronic sinus disease with nasal polyps, and respiratory reactions triggered by aspirin or similar pain relievers (NSAIDs like ibuprofen and naproxen). People with AERD don’t just get a mild stomachache from aspirin. Their airways can tighten, their nose runs heavily, and they may experience significant breathing difficulty.
The condition affects the body’s inflammatory balance. In AERD, blocking a specific enzyme involved in inflammation (the same enzyme aspirin targets) triggers an overproduction of inflammatory molecules in the lungs and sinuses. Paradoxically, once the body is pushed past that initial reaction through desensitization, daily aspirin actually helps suppress the underlying inflammation driving the disease.
Desensitization is typically recommended when nasal polyps grow back rapidly after surgery, when sinus disease isn’t responding to standard treatments, or when a patient needs frequent courses of oral steroids to keep respiratory symptoms under control. It offers no benefit for people who tolerate aspirin normally, even if they have nasal polyps or asthma.
How AERD Is Diagnosed
An aspirin challenge, where a patient takes aspirin in a monitored setting and doctors measure their airway and nasal response, is the gold standard for confirming AERD. A history of an asthma attack after taking aspirin or ibuprofen is suggestive but not always reliable. About 16% of patients who believed they had AERD based on their history actually tested negative when formally challenged. AERD can also be underdiagnosed in people who have never happened to take aspirin during the period of active disease.
Imaging is also a useful clue. CT scans of the sinuses show complete opacification (the sinuses are entirely blocked) in nearly all AERD patients. Normal sinus imaging essentially rules the diagnosis out. Other common features include loss of smell, severe nighttime nasal congestion, sleep disruption, and asthma that may have started before or after the sinus problems appeared.
What Happens During the Procedure
Aspirin desensitization takes place in a clinical setting, typically an allergist’s office or hospital, where lung function and vital signs can be monitored closely. The traditional approach spans three or more days using a protocol that starts with a small dose (around 20 to 40 mg) and increases every 90 minutes to three hours through a series of steps: 40.5 mg, 81 mg, 162.5 mg, and 325 mg.
At each step, doctors measure lung function with a breathing test and track nasal symptoms. Most patients with AERD will have a reaction at some point during the escalation, often a drop in lung function or worsening nasal congestion and runny nose. When that happens, the process pauses for about three hours while the reaction is monitored and treated if needed. Once the patient recovers, the same triggering dose is repeated. If it’s tolerated on the second try, the next higher dose is given. The procedure continues until the patient has taken at least 325 mg of aspirin without reacting, at which point they are considered desensitized.
Newer protocols have condensed this into a single day with 90-minute intervals between doses, making the process more practical for both patients and clinicians.
Staying Desensitized: The Daily Requirement
Desensitization is not permanent on its own. To maintain tolerance, you must take aspirin every single day without interruption. The minimum effective dose is 325 mg daily, which is enough to keep the desensitized state and safely allow use of other NSAIDs. However, many patients take between 325 mg and 1,300 mg per day to get the full therapeutic benefit for their sinus and asthma symptoms. The right dose varies from person to person. If you stop taking aspirin for more than about 48 hours, sensitivity can return and the full desensitization procedure would need to be repeated.
How Well It Works
For AERD patients, the results are significant. Daily aspirin therapy after desensitization reduces and delays nasal polyp regrowth in more than 70% of patients. Beyond the sinuses, patients typically need less steroid medication, experience improved asthma control, and have fewer emergency room visits or hospitalizations for asthma flares. For many people with AERD, this combination of desensitization plus daily aspirin is one of the most effective long-term treatments available.
The benefits appear to come from aspirin’s ability to dampen specific inflammatory pathways that are overactive in AERD. Research shows aspirin suppresses key signaling in immune cells that drive the allergic inflammation behind the disease, reducing the production of inflammatory molecules that fuel polyp growth and airway tightening.
Aspirin Desensitization for Heart Patients
A separate application exists for people with coronary artery disease who are allergic to aspirin but need it for heart protection, particularly before or after procedures like stent placement. In these cases, the protocol is faster and the goal is different: the aim is simply to achieve tolerance so the patient can safely take a low daily dose for cardiovascular protection, not to treat a respiratory condition.
A study of 24 patients with both stable and acute coronary disease found rapid oral desensitization was successful in 92% of cases. The two patients who didn’t tolerate the procedure experienced brief episodes of airway tightening that resolved quickly with treatment. Previous reactions in these patients ranged from hives and facial swelling to respiratory symptoms and severe allergic-type reactions. Patients with a history of full anaphylaxis to aspirin or those with unstable heart conditions generally are not considered safe candidates for desensitization due to the risk of a severe reaction in an already compromised state.
Who Should Not Undergo the Procedure
Aspirin desensitization is not appropriate for everyone with aspirin sensitivity. People who have experienced systemic anaphylaxis to aspirin, where the reaction involved a dangerous drop in blood pressure or widespread organ involvement, are generally excluded because the risk of a fatal reaction during the procedure is too high. Patients with chronic hives triggered by aspirin (chronic idiopathic urticaria) are also not considered good candidates, as the desensitization approach does not work well for that type of reaction.
For cardiac patients, desensitization should typically happen after any acute heart event has been stabilized rather than during an emergency. And the therapy provides no benefit for people with nasal polyps or asthma who don’t actually react to aspirin, so confirming a true aspirin sensitivity through a formal challenge is an important step before committing to lifelong daily aspirin use.